Teva Identifies Teriparatide Importance Amid US Launch Drought

Israeli Firm Sees 15% North America Gx Sales Decline In Q1

Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.

Balloons
Teva singled out teriparatide among its 2022 opportunities • Source: Shutterstock

Teva has described its proposed generic version of Eli Lilly’s Forteo (teriparatide) as “the most important” potential US generic launch this year, “one which would be a significant contributor to our sales in 2022,” despite development partner Antares Pharma electing not to include any US teriparatide revenues in its 2022 annual financial guidance.

Low-competition, high-margin approvals and launches in the US are crucial to Teva’s prospects this year, one which the Israeli giant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business